Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Novavax Inc (NVAX) Price & Performance

Flagstar Bank NATrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Novavax Inc — how do they compare? Flagstar Bank NA trades at $14.3 (market cap $5.89B), while Novavax Inc trades at $7.89 (market cap $1.31B). The key difference: Flagstar Bank NA is far larger — about 4.5× Novavax Inc's market cap, and Flagstar Bank NA pays a 0.28% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

FLGNVAX
Market Cap
$5.89B$1.31B
Sector
FinancialsHealth
52-Week High
$15.36$11.19
52-Week Low
$10.72$6.22
Dividend Yield
0.28%
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $14.285, up 1.96% today, with a bullish technical signal from moving averages and a consensus analyst price target of $16.85. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and dividend payments reflect strong capital management, while proprietary technology initiatives aim to bolster long-term growth.

The outlook is cautiously optimistic, with potential upside from execution on strategic initiatives and valuation support from a low P/B ratio of 0.77. Risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. Analyst sentiment is positive with no sell ratings, but investors should monitor fee income trends and credit quality.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX